Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2010

View Archived Issues

Actimis discloses novel isotopically enriched prostanoid DP2 receptor antagonists

Arena Pharmaceuticals claims new receptor S1P1 agonists

NeuroSearch discovers new voltage-gated K(V)7 potassium channel activators

Boehringer Ingelheim discloses candidate hepatitis C therapeutic BI-201335

Acucela claims new agents for treatment of ophthalmic disorders

Novel histamine H3 receptor antagonists patented by Evotec Neurosciences

Duke University researchers identify new metabolic biomarker of cardiovascular events

Data from TROPICS 3/4 trials support tenecteplase for improvement hemodialysis catheter function

Clinical data disclosed on bevacizumab in metastatic CRC and HCC

Pfizer details preclinical characteristics of new beta-secretase inhibitors

Antisoma halts ATTRACT-1 phase III trial of ASA-404

Potent and selective CB1 receptor antagonist shows promise in mouse model of obesity

Primera Bioscience Research's project with the Hospital for Sick Children achieves major milestone

AdventRx to discuss ANX-530 NDA for NSCLC with FDA

Bioalliance Pharma's antiemetic Setofilm approved in Europe

Cellceutix reports preclinical data on KM-391 for autism

Cipher submits NDS to Health Canada for CIP-Tramadol ER for moderately severe pain

MannKind achieves milestones in collaboration with Multiple Myeloma Research Foundation

Novavax releases results from phase II trivalent seasonal influenza vaccine trial

Renovo's phase III Juvista trial fully recruited and on schedule

LCT receives approval to evaluate higher dose of DiabeCell in unstable diabetes

EMA approves combination of Xeloda and oxaliplatin for adjuvant treatment of early colon cancer

Multaq approved and launched in U.K. by sanofi-aventis for management of atrial fibrillation

GenVec discontinues phase III PACT trial of TNFerade following interim analysis

Clinuvel advances afamelanotide to phase II following FDA approval of IND

EMA grants orphan drug designation to Protalix's taliglucerase alfa for Gaucher's disease

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...